EyePoint(NASDAQ) EYPT

EyePoint, Inc. creates medical treatments for people suffering from serious vision-threatening eye diseases. Its products deliver medicine slowly inside the eye to treat retinal conditions. This approach helps patients avoid the need for frequent and uncomfortable eye injections.

Medicine for the Eye

• DURAVYU: Investigational treatment that uses a tiny bioerodible insert to release medicine slowly for patients with retinal diseases.
• Durasert E: Proprietary technology designed to provide sustained drug delivery inside the eye for several months.
• YUTIQ: Intravitreal implant used to treat chronic inflammation that affects the back of the eye.
• DEXYCU: Intraocular suspension used to manage inflammation after a patient has cataract surgery.

Steps Toward New Treatments

• Entered a settlement agreement with the U.S. government on July 17, 2026, to resolve civil and administrative liability.
• Appointed Tarek S. Hassan as Chief Strategic Science Officer on July 13, 2026, to lead scientific strategy.
• Completed patient enrollment for two pivotal Phase 3 clinical trials of DURAVYU for diabetic macular edema in July 2026.
• Presented new preclinical data in May 2026 showing how its lead candidate inhibits specific inflammatory signals in the eye.

Sustained Drug Delivery

EyePoint uses its proprietary Durasert technology to turn drugs that usually require frequent injections into long-term treatments. The company manages its own manufacturing facility in Northbridge, Massachusetts, to produce its clinical and commercial supplies.

By the Numbers

• License and collaboration revenue fell 90% to $0.5 million for the three-month period ended June 30, 2026.
• Research and development costs rose 51% to $83.6 million for the three-month period ended June 30, 2026.
• Net loss was $94.5 million for the three-month period ended June 30, 2026.
• Cash, cash equivalents, and investments totaled $180.5 million at June 30, 2026, which the company expects will fund operations into late 2027.
• Sold common stock through an at-the-market facility for gross proceeds of $20.2 million during the three-month period ended June 30, 2026.

The Road Ahead

EyePoint is transitioning from a provider of commercial eye drugs to a clinical-stage developer focused on long-acting retinal therapies. Its future evolution depends on the successful clinical development and regulatory approval of its lead candidate, DURAVYU.